EBT-104

N/A

Report date: 2025/05/16 17:55:09

Base Information

Drug NameEBT-104
Drug Alias NameEBT-104EBT 104
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionE3 ubiquitin-protein ligase ICP0 inhibitorsmRNA export factor inhibitors
TargetsE3 ubiquitin-protein ligase ICP0mRNA export factor
Therapy Area/IndicationsHerpes Simplex Virus Type 1 InfectionsKeratitisHerpes Simplex
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, Berkeley
China Registration ClassN/A

Develop Information

Active CompaniesExcision BioTherapeutics Inc
Inactive CompaniesUniversity Of California, Berkeley
Active IndicationsHerpes Simplex Virus Type 1 InfectionsKeratitis
Inactive IndicationsHerpes Simplex

Other Information

ATC CodeN/A
Related LinksN/A